IBIO - Second tier COVID-19 vaccine developers under pressure on positive Pfizer/BioNTech data

Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start by year-end or early January.Selected tickers: Inovio Pharmaceuticals ([[INO]] -15.2%), iBio ([[IBIO]] -4.0%), Altimmune ([[ALT]] -24.5%), Vaxart ([[VXRT]] -14.6%), Heat Biologics ([[HTBX]] -6.1%)

For further details see:

Second tier COVID-19 vaccine developers under pressure on positive Pfizer/BioNTech data